Bowhead Specialty Holdings Inc

BOW remains in a Stage 2 advancing uptrend with rising EMAs underpinning higher highs and higher lows, but overbought RSI readings and exhaustion candles at recent highs warn of near-term fatigue. We defer buying and stalk for a pullback into the rising 9/21 EMA support zone as the optimal entry region.

• ↑Q1 GWP rose 24% YoY to $217M; adjusted net income up 40% to $16M (EPS $0.48).
• ↑Expense ratio declined to 28.4% and combined ratio held at ~95.3%, showing disciplined underwriting.
• ↓Intensifying specialty insurance competition may erode pricing discipline in casualty lines.